Phaseline

Companies › Inhatarget Therapeutics

Inhatarget Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CIS-DPI (Cisplatin-based Dry Powder for Inhalation)
DNA cross-linking agent delivered via pulmonary inhalation
–Phase 1NSCLC (advanced Non-small Cell Lung Cancer)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06896890CIS-DPI (Cisplatin-based Dry Powder for Inhalation)Phase 1NSCLC (advanced Non-small Cell Lung Cancer)OncologyOct 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.